Insurers, CVS Call on FDA to Finalize Interchangeable Biosimilar Guidance

The US Food and Drug Administration (FDA) should finalize guidance on interchangeable biosimilars to increase cost savings, a letter from a group of 17 insurers and other groups, including Kaiser Permanente, Blue Cross Blue Shield and CVS, to FDA Commissioner Scott Gottlieb said on Thursday.